Market capitalization | $25.51m |
Enterprise Value | $25.17m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 629.25 |
P/S ratio (TTM) P/S ratio | 637.75 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | -72.34% |
Revenue (TTM) Revenue | $40.00k |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
1 Analyst has issued a forecast BioSig Technologies, Inc.:
1 Analyst has issued a forecast BioSig Technologies, Inc.:
Sep '24 |
+/-
%
|
||
Revenue | 0.04 0.04 |
71%
71%
|
|
Gross Profit | -0.21 -0.21 |
59%
59%
|
|
EBITDA | -17 -17 |
40%
40%
|
EBIT (Operating Income) EBIT | -18 -18 |
40%
40%
|
Net Profit | -15 -15 |
49%
49%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
BioSig Technologies, Inc. is a medical technology company. It engages in the development of a proprietary biomedical signal processing platform designed to improve the electrophysiology (EP) marketplace. The firm is preparing to commercialize its PURE EP System. BioSig Technologies was founded by Kenneth L. Londoner on February 24, 2009 and is headquartered in Westport. CT.
Head office | United States |
CEO | Anthony Amato |
Employees | 4 |
Founded | 2009 |
Website | www.biosig.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.